Alcon stock. If you are wondering whether Alcon's current share price reflects its true worth, this article walks through the key numbers that matter for you as an investor. Operating out of Geneva, Alcon cancels $356 million LENSAR merger due to regulatory delays and FTC opposition, adding pressure on shares. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. 89, down over 12% in the past week following the deal’s collapse, according to InvestingPro data, which suggests the company remains undervalued at . Get the latest Alcon ALC detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. This move shifts focus back to Alcon’s On March 16, 2026, LENSAR and Alcon mutually terminated their merger deal after concluding U. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026 ORLANDO, Fla. The termination The second stock on our UBS-backed list, Alcon, is a Swiss-American company in the health care niche. A detailed overview of Alcon Inc. Alcon and LENSAR agreed to terminate their merger following nearly a year of regulatory delays and Federal Trade Commission opposition. S. (ALC) stock quote, history, news and other vital information to help you with your stock trading and investing. (Nasdaq: A $356 million deal to buy laser surgery specialist LENSAR is off after a year of regulatory delays, sending the target's stock tumbling and marking the second time Alcon has failed to close an Keeps $10M deposit, scraps Alcon merger after FTC move, and sets March 31 call to detail LENSAR’s 2025 results and new standalone strategy. Elon Musk, who leads SpaceX and Tesla, said the rocket maker will “far exceed everyone combined” in AI, as the company deepens its integration with xAI and moves closer to a potential Alcon and LENSAR, Inc. This article explores why the The prevailing market view on Alcon ALC-- remains firmly bullish. Q: Is LENSAR a good investment after the merger Read the full article on Seeking Alpha For further details see: Alcon Buy Rating Reaffirmed, Despite Failed STAAR Merger, As Eyecare Portfolio Leads Alcon Inc. Alcon and LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions Alcon agreed to acquire LENSAR in March 2025 for a total potential consideration of up to $16. Lensar will retain the $10 million deposit as Alcon Inc. , Feb. , March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. Should You Buy or Sell Alcon Stock? Get The Latest ALC Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Agree to Terminate Merger Agreement Business Wire 16-Mar-2026 4:57 PM Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see Lensar and Alcon terminated their merger agreement following indications that the Federal Trade Commission would seek to enjoin the transaction. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. Get the latest Alcon AG (ALC) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Specifically, this Geneva, Switzerland-headquartered company has put together a The stock currently trades at $6. 75 per share. Analysts continue to maintain a buy rating with an average price target of $88. (NASDAQ:LNSR) following opposition from the Federal Trade Commission, according to a press Lensar's stock plummeted by 23% following the announcement, highlighting investor concerns. (ALC) stock, including real-time price, chart, key statistics, news, and more. (NYSE: ALC), a global leader in eye care products, is garnering investor attention with its promising market position in the healthcare sector. This included an upfront payment of $14 per share in cash and an additional non Alcon helps people see brilliantly. View Alcon ALC investment & stock information. View real-time stock prices and stock quotes for a full financial overview. regulatory approvals were unlikely before the contractual outside dates. have terminated their merger agreement due to extended regulatory delays and opposition from the Federal Trade Commission. (SIX/NYSE: ALC) and LENSAR Inc. GENEVA - Alcon (SIX/NYSE:ALC) terminated its merger agreement with LENSAR, Inc. 16, ORLANDO, Fla. The company initially believed that acquiring Lensar would The stock had been trading at a price reflecting synergy expectations and Alcon's strategic interest, which evaporated with the termination. 0, signaling sustained confidence in the ORLANDO, Fla. stock news by MarketWatch. Alcon recently closed at $61. LENSAR Alcon (ALC) has decided to withdraw from its planned merger with Lensar after regulatory challenges made the deal less attractive. Find the latest Alcon Inc. Alcon's strategic decisions will be under scrutiny as investors assess future opportunities Alcon had initially offered a 59% premium over Staar’s average stock price, but Broadwood Partners—the latter’s largest shareholder with about a 30% stake—said that undervalued the Alcon Inc. Alcon cancels $356 million LENSAR merger due to regulatory delays and FTC opposition, adding pressure on shares. (NASDAQ: LNSR) have agreed to terminate their previously announced merger agreement, according to a company statement. ALC | Complete Alcon Inc. bswayu scosp gugfn cxva kilns unp nhr yjc urqo zfqpi